These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 20443171)

  • 1. [Long term effect of interferon-beta on disease severity in relapsing-remitting multiple sclerosis patients].
    Patrucco L; Rojas JI; Cristiano E
    Rev Neurol; 2010 May; 50(9):529-32. PubMed ID: 20443171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New natural history of interferon-beta-treated relapsing multiple sclerosis.
    Trojano M; Pellegrini F; Fuiani A; Paolicelli D; Zipoli V; Zimatore GB; Di Monte E; Portaccio E; Lepore V; Livrea P; Amato MP
    Ann Neurol; 2007 Apr; 61(4):300-6. PubMed ID: 17444502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical assessment of the course of relapsing-remitting multiple sclerosis in patients treated with interferon beta].
    Pokryszko-Dragan A; Bilińska M; Gruszka E; Dubik-Jezierzańska M
    Pol Merkur Lekarski; 2005 Nov; 19(113):654-8. PubMed ID: 16498805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-life impact of early interferon beta therapy in relapsing multiple sclerosis.
    Trojano M; Pellegrini F; Paolicelli D; Fuiani A; Zimatore GB; Tortorella C; Simone IL; Patti F; Ghezzi A; Zipoli V; Rossi P; Pozzilli C; Salemi G; Lugaresi A; Bergamaschi R; Millefiorini E; Clerico M; Lus G; Vianello M; Avolio C; Cavalla P; Lepore V; Livrea P; Comi G; Amato MP;
    Ann Neurol; 2009 Oct; 66(4):513-20. PubMed ID: 19847899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis.
    Patti F; Amato MP; Bastianello S; Caniatti L; Di Monte E; Ferrazza P; Goretti B; Gallo P; Morra VB; Lo Fermo S; Picconi O; Tola MR; Trojano M;
    Mult Scler; 2010 Jan; 16(1):68-77. PubMed ID: 19995846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
    Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
    Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D
    Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of interferon beta treatment in relapsing-remitting multiple sclerosis: an Italian cohort study.
    Russo P; Paolillo A; Caprino L; Bastianello S; Bramanti P
    J Eval Clin Pract; 2004 Nov; 10(4):511-8. PubMed ID: 15482413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting beta-interferon failure in relapsing-remitting multiple sclerosis.
    O'Rourke K; Walsh C; Antonelli G; Hutchinson M
    Mult Scler; 2007 Apr; 13(3):336-42. PubMed ID: 17439902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience.
    Pozzilli C; Prosperini L; Sbardella E; De Giglio L; Onesti E; Tomassini V
    Neurol Sci; 2005 Dec; 26 Suppl 4():S174-8. PubMed ID: 16388353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of relapsing-remitting multiple sclerosis treatment with interferon beta-1b results of a three-year follow-up study.
    Jesić A; Stefanović D; Delibasić N; Semnic M; Sakallasz L; Dobrenov D; Zivanović Z; Rabi-Zikić T; Zikić M
    Acta Clin Croat; 2009 Jun; 48(2):183-6. PubMed ID: 19928420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Long-term application of the multiple sclerosis functional composite test in Debrecen, Hungary].
    Mezei Z; Bereczki D; Csiba L; Csépány T
    Ideggyogy Sz; 2006 Nov; 59(11-12):442-7. PubMed ID: 17203882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical impact of interferon beta antibodies in relapsing-remitting MS.
    Perini P; Calabrese M; Biasi G; Gallo P
    J Neurol; 2004 Mar; 251(3):305-9. PubMed ID: 15015010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measures in the first year of therapy predict the response to interferon beta in MS.
    Río J; Castilló J; Rovira A; Tintoré M; Sastre-Garriga J; Horga A; Nos C; Comabella M; Aymerich X; Montalbán X
    Mult Scler; 2009 Jul; 15(7):848-53. PubMed ID: 19542263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of relapses over early progression of disability in multiple sclerosis patients treated with beta-interferon.
    Bosca I; Coret F; Valero C; Pascual AM; Magraner MJ; Landete L; Casanova B
    Mult Scler; 2008 Jun; 14(5):636-9. PubMed ID: 18566027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.
    Koch-Henriksen N; Sørensen PS; Christensen T; Frederiksen J; Ravnborg M; Jensen K; Heltberg A; Kristensen O; Stenager E; Petersen T; Hansen T;
    Neurology; 2006 Apr; 66(7):1056-60. PubMed ID: 16510769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
    Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X
    Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment.
    Trojano M; Pellegrini F; Paolicelli D; Fuiani A; Zimatore GB; Tortorella C; Simone IL; Patti F; Ghezzi A; Portaccio E; Rossi P; Pozzilli C; Salemi G; Lugaresi A; Bergamaschi R; Millefiorini E; Clerico M; Lus G; Vianello M; Avolio C; Cavalla P; Iaffaldano P; Direnzo V; D'Onghia M; Lepore V; Livrea P; Comi G; Amato MP;
    J Neurol Sci; 2009 Nov; 286(1-2):109-13. PubMed ID: 19615696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis.
    Portaccio E; Zipoli V; Siracusa G; Sorbi S; Amato MP
    Eur Neurol; 2008; 59(3-4):131-5. PubMed ID: 18057899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials.
    Bates D
    Neurology; 2011 Jan; 76(1 Suppl 1):S14-25. PubMed ID: 21205678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.